1. What is METHOTREXATE EBEWE and what is it used for?
METHOTREXAT “EBEWE” is a yellow, round, scored tablet (yellow to red with spots from methotrexate).
It is packaged as 1 piece in a box and 50 or 100 tablets in a plastic (polypropylene) bottle. METHOTREXAT “EBEWE” is a drug called antimetabolite, which prevents the proliferation of tumor cells.
METHOTREXAT “EBEWE” is used to treat joint inflammation (rheumatoid arthritis) in adults.
METHOTREXAT “EBEWE” is used to treat severe, uncontrollable psoriasis (psoriasis) that has not responded to other treatments.
METHOTREXAT “EBEWE” is used alone or in combination with other cancer drugs to treat various types of cancer:
blood cancer (acute leukemia),
Lymph cancers (Non-Hondgkin lymphoma),
Soft tissue and bone tumor (osteogenic sarcoma),
Breast, lung, head and neck, bladder, cervix, ovary and testicular cancers
2. How to use METHOTREXATE EBEWE?
Instructions for proper use and dose/frequency of administration
It is administered orally.
Swallow METHOTREXAT “EBEWE” with a glass of water 1 hour before or 1.5-2 hours after meals. Do not chew your tablets.
METHOTREXAT “EBEWE” should be used once a week.
Application route and method
You should always use METHOTREXAT “EBEWE” as advised by your doctor. If you are unsure, consult your doctor or pharmacist.
Depending on your disease, your doctor will inform you about the frequency of administration of METHOTREXAT “EBEWE” and how long your treatment will last.
In the treatment of joint inflammation (rheumatoid arthritis):
Take your tablets usually once a week, 7.5 mg once a day, or 2.5 mg 3 times a day (12 hours apart). The weekly dose may vary between 7.5 mg-20 mg depending on your response to treatment. If you take it every day, it causes very serious harmful effects.
In the treatment of psoriasis (psoriasis):
The recommended dose is 10-25 mg once a week. The dosage will be adjusted by your doctor according to your response to the disease and your general health.
In cancer treatment:
Before starting treatment, your doctor may administer a trial dose of 5-10 mg intravenously to see the side effects of your medication.
METHOTREXAT “EBEWE” is usually given as a single daily dose for a period not exceeding 5 consecutive days, with each dose not exceeding 30 mg per 1 m2 of your body’s surface area. It is recommended to leave at least two weeks of drug-free time between your treatments so that the function of your bone marrow to produce your blood cells can return to normal.
3. What are the possible side effects?
Like all medicines, there may be side effects in people who are sensitive to the substances contained in METHOTREXATE EBEWE.
The most common side effects include oral inflammation, decreased white blood cell count, nausea and abdominal pain. Very rarely, life-threatening allergic reactions to methotrexate (suddenly appearing hives, swelling of the hands, feet, face, lips, mouth or throat (swelling of the mouth and lips may cause difficulty in swallowing or breathing), wheezing and feeling like fainting. ) is developed. Other reported side effects are eye irritation, weakness, extreme fatigue, vascular inflammation, blood poisoning, joint pain/muscle pain, chills and fever, dizziness, decreased sexual desire/impotence, and decreased resistance to infection. Opportunistic infections (sometimes fatal blood poisoning) have been reported in patients taking methotrexate for cancer and non-cancerous diseases, most commonly a certain type of lung inflammation (Pneumocystis carinii-induced lung inflammation). Other reported infections are pneumonia caused by viruses, fungi and bacteria, diseases caused by bacteria and fungi (nocardiosis, histoplasmosis, cryptococcosis), shingles (a rash and painful disease caused by the Herpes zoster virus), herpes, generalized herpes with liver inflammation and a virus (cytomegalovirus) infection (including cytomegalovirus-induced lung inflammation).
Possible side effects are listed according to the following categories.
Very common: May occur in at least 1 in 10 patients.
Common: less than 1 in 10 patients, but more than 1 in 100 patients.
Uncommon: less than 1 in 100 patients, but more than 1 in 1000 patients. Rare: less than 1 in 1000 patients, but more than 1 in 10,000 patients.
Very rare: less than 1 in 10,000 patients.
Not known: Cannot be estimated from the available data.
Loss of appetite
Sores (ulcer) on the inner surface of the mouth
Increase in liver enzyme levels
Decreased number of blood cells (white/red blood cells or platelets)